Selank
Selank (Synthetic Tuftsin Analog TP-7)
Also known as: SELANK, TP-7, Thr-Lys-Pro-Arg-Pro-Gly-Pro
Prompted by Jack Butcher (Visualize Value) · AI-authored by Claude · Research-sourced
A synthetic tuftsin analog approved in Russia as an anxiolytic. Modulates GABA and serotonin systems to reduce anxiety without sedation or cognitive impairment — often paired with Semax.
Quick Facts
Approved in Russia as an anxiolytic and nootropic medication. Not FDA-approved in the United States. Not a controlled substance.
Overview
Selank is a synthetic heptapeptide derived from tuftsin (Thr-Lys-Pro-Arg), an endogenous immunomodulatory peptide, with the addition of a Pro-Gly-Pro C-terminal sequence for enhanced metabolic stability. It was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, the same laboratory that created Semax.
Approved for clinical use in Russia since 2009, Selank is prescribed as an anxiolytic and nootropic. It is notable for producing anxiolytic effects comparable to benzodiazepines without sedation, cognitive impairment, dependence, or withdrawal symptoms — limitations that characterize conventional anti-anxiety medications.
Selank bridges two pharmacological domains: it functions as both an anxiolytic and an immunomodulator. Its parent molecule tuftsin is a naturally occurring tetrapeptide released from the Fc region of IgG, linking the immune and nervous systems through a shared peptide signaling pathway.
Mechanism of Action
Selank exerts its anxiolytic effects primarily through modulation of the GABAergic system. It allosterically enhances GABA-A receptor sensitivity, increasing inhibitory neurotransmission without directly binding the benzodiazepine site. This produces anxiolysis without the sedation and dependency associated with classical benzodiazepine agonists.
The peptide significantly influences serotonin (5-HT) metabolism. Studies demonstrate that Selank stabilizes enkephalin degradation and modulates the balance of serotonin and its metabolites in brain structures including the hypothalamus, hippocampus, and frontal cortex. It inhibits the activity of enzymes that degrade enkephalins, thereby prolonging endogenous opioid peptide signaling.
Selank modulates expression of brain-derived neurotrophic factor (BDNF) and influences the MAPK/ERK signaling pathway, contributing to neuroplasticity and neuroprotective effects. Gene expression analysis has shown that Selank affects the transcription of 36 genes related to GABAergic neurotransmission.
As a tuftsin analog, Selank retains immunomodulatory properties. It influences IL-6, T-helper cell balance, and monocyte function, providing a neuroimmune dimension to its mechanism. This dual anxiolytic-immunomodulatory profile is unique among peptide-based therapeutics.
Research Summary
Clinical research on Selank, primarily from Russian medical literature, demonstrates consistent anxiolytic effects. In a randomized clinical study of patients with generalized anxiety disorder (GAD), Selank produced significant reductions in Hamilton Anxiety Rating Scale scores comparable to the benzodiazepine medazepam, but without sedation or cognitive impairment.
Gene expression studies have been particularly revealing. Microarray analysis showed that Selank significantly alters expression of genes involved in GABAergic neurotransmission, including multiple GABA-A receptor subunit genes. This genomic-level evidence supports the clinical observations of anxiolytic effects.
Serotonin metabolism research demonstrated that Selank modulates the concentration of serotonin and 5-HIAA (its primary metabolite) in the hypothalamus and frontal cortex. The effect is normalizing rather than purely stimulatory or inhibitory, suggesting adaptogenic properties.
Immunomodulatory studies confirm that Selank influences cytokine expression, enhances phagocytic activity, and normalizes immune parameters in stressed animals. This positions Selank at the intersection of psychoneuroimmunology.
Limitations: As with Semax, the clinical evidence base consists predominantly of Russian studies. Large-scale, placebo-controlled trials conforming to Western regulatory standards are lacking.
Key References
Selank administration affects the expression of some genes involved in GABAergic neurotransmission
Zozulya AA, et al. · Frontiers in Pharmacology (2014) · 10.3389/fphar.2014.00186
Microarray analysis demonstrated that Selank modulates expression of 36 genes related to GABAergic signaling, including GABA-A receptor subunit genes, providing molecular evidence for its anxiolytic mechanism.
Anxiolytic-like effect of selank in rats
Semenova TP, et al. · Bulletin of Experimental Biology and Medicine (2010) · 10.1007/s10517-010-0898-0
Demonstrated that Selank produces significant anxiolytic effects in the elevated plus maze without sedation or motor impairment, comparable to benzodiazepines but without their characteristic side effects.
Selank has an anxiolytic effect and inhibits enkephalin-degrading enzymes
Kozlovskii II, Danchev ND. · Bulletin of Experimental Biology and Medicine (2003) · 10.1023/A:1024244824118
Showed that Selank produces anxiolytic effects partly through inhibition of enkephalin-degrading enzymes, prolonging the action of endogenous opioid peptides in the brain.
Effect of Selank on serotonin metabolism in the brain of rats
Narkevich VB, et al. · Bulletin of Experimental Biology and Medicine (2008) · 10.1007/s10517-008-0173-1
Demonstrated that Selank modulates serotonin and 5-HIAA levels in the hypothalamus and frontal cortex, supporting its role in normalizing serotonergic neurotransmission.
Protocols
Anxiolytic / anti-anxiety
Standard Russian clinical dosing. The 0.15% solution delivers approximately 75 mcg per drop. Best started at the lower end. Effects are often noticed within the first few days, with full anxiolytic benefit developing over 1–2 weeks of consistent use.
Cognitive enhancement / nootropic stack
Often combined with Semax for a comprehensive nootropic and anxiolytic stack. Selank addresses the anxiety component while Semax provides stimulatory cognitive enhancement. Avoid evening dosing if any stimulating effects are noticed.
Immunomodulatory support
Used in Russian clinical practice for immune support. Higher doses used for acute immune challenge. Limited Western data on immune-specific protocols.
Side Effects & Safety
| Frequency | Effect |
|---|---|
| common | Nasal irritation Mild tingling or slight burning upon intranasal administration. Transient and generally diminishes with continued use. |
| uncommon | Fatigue or drowsiness Occasionally reported, though Selank is generally non-sedating. May indicate individual sensitivity or excessive dosing. |
| uncommon | Headache Mild headache reported infrequently, more common at higher doses. |
| rare | Allergic reaction As a peptide, there is a theoretical risk of hypersensitivity. Extremely rare in clinical practice. |
Contraindications
- —Known hypersensitivity to tuftsin or related peptides
- —Pregnancy or breastfeeding (insufficient safety data)
- —Active autoimmune conditions (theoretical concern due to immunomodulatory effects)
- —Concurrent use of benzodiazepines or other GABAergic drugs (potential interaction)
Reconstitution & Storage
Related Peptides
Most commonly paired with Semax for a comprehensive cognitive and anxiolytic stack. Semax provides stimulatory nootropic effects and BDNF upregulation while Selank delivers anxiolysis and emotional stabilization. The combination addresses both cognitive performance and stress resilience without the trade-offs of pharmaceutical alternatives.